Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ACTRN12626000232336) titled 'Relative Bioavailability Study of ACE-2223-1 Liquid vs Solid Formulation in Healthy Adult Participants (Part C)' on Feb. 24.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Primary Sponsor: Acelot, Inc.
Condition:
Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Neurological - Neurodegenerative diseases
Intervention:
Part C will consist of an open-label, randomised sequence, 2-way crossover investigation to compare the relative bioavailability (RBA) of a single ACE-2223-1 dose using two different formulations: one liquid formula...